Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Nephrectomy may benefit select renal cancer patients based on risk factors
Key clinical point: Among metastatic renal cell carcinoma patients who require medical therapy, those with only one International Metastatic Renal Cell Carcinoma Database Consortium risk factor may benefit from cytoreductive nephrectomy.
Major finding: Among patients treated with nephrectomy plus sunitinib, median overall survival was 31.4 months for those with just one risk factor, and 17.6 months for those with two or more (hazard ratio, 1.68; 95% confidence interval, 1.10-2.57; P = .01).
Study details: A follow-up analysis of the CARMENA trial, which included 450 patients with metastatic renal cell carcinoma randomized to nephrectomy followed by sunitinib or sunitinib alone.
Disclosures: Dr. Méjean reported disclosures related to Ipsen, Novartis, Pfizer, Bristol-Myers Squibb, Janssen, Sanofi and Roche.
Méjean A et al. ASCO 2019, Abstract 4508.